US FDA May Change Advisory Committee Planning, Member Screening
Departing Commissioner says that special government employee procedure especially is in need of reform.
You may also be interested in...
FDA's Peter Stein calls idea "useful"; rare disease experts would temporarily serve on standing advisory committees when needed.
Attorneys' proposal aims to better connect dispersed rare disease expertise within FDA's drug, biologic, and device centers through more leadership, new advisory committee.
Panel members’ curricula vitae will now be released without a review and redaction of potentially confidential information; FDA’s policy change is part of a settlement of lawsuit with Public Citizen.